2) How many druggable pockets can be found for a MAPK protein?

Ans:— Firstly, a druggable pocket is an interactive, 3D representation of a

binding pocket on a protein surface. Users can manipulate it, usually to vis-
ually explore possible ligand binding sites. They can also adjust or define the
pocket region for docking or volume measurement. Additionally, they can re-
fine the position or shape of the pocket grid used in computational analyses,
such as docking box, site volume, or pocket map. It’s not a biological term;
it’s a feature in molecular visualisation or docking software.
I selected P38MAPK

First, I found the 3D structure of the MAPK protein I wanted from the Protein Data
Bank at [Link]. For example, I searched for “p38 MAPK”. Then, I downloaded
2
the PDB file of that [Link], I went to the DoGSiteScorer web server by
visiting [Link]
After that, I clicked on “Upload PDB File” to upload my protein file, or if sup-
ported, I directly provided the PDB ID of my MAPK protein.
Then, I started the pocket detection analysis by submitting the protein structure.
The tool scanned both the surface and interior of the protein to find possible
binding pockets.
Once the analysis was done, usually in a few minutes, I looked at the detected
pockets. I checked details like the volume, depth, hydrophobicity, and especially
the druggability score. Pockets with higher druggability scores were more likely
to bind drug-like molecules.
Finally, I downloaded the results, including visualisations and the coordinates of
I discovered 4 pockets :-
3. Drug resistance is a fast rising menace in the society. Give an
example of a protein that resisted binding to existing drugs..
What caused the resistance (explain with structure)?
Ans :—
An example of a protein that resisted binding to existing drugs is DNA gyrase,
a bacterial enzyme targeted by fluoroquinolone antibiotics like ciprofloxacin.
Resistance to these drugs is mainly caused by point mutations in the
quinolone resistance-determining region (QRDR) of the DNA gyrase subunit
GyrA .
Structural cause of resistance:
1) Fluoroquinolones inhibit DNA replication by binding to the DNA-en-
zyme complex. Mutations in the GyrA subunit change amino acids at the drug-
binding site.
2) These mutations reduce the binding affinity between fluoroquinolones
and DNA gyrase by altering the shape and chemical environment of the
pocket where the drug normally binds.
3) Crystal structures comparing wild-type and mutated gyrase DNA drug
complexes show that resistant mutations cause loss of key contacts and
sometimes steric hindrance, preventing effective drug binding.
4) As a consequence, the drug cannot stabilise the cleaved DNA-enzyme

7)What are Intrinsically disordered proteins (IDP). What are their

functions inside the cell?How would you evaluate if a protein or a do-
main is intrinsically disordered? 2

Intrinsically disordered proteins (IDPs) or intrinsically disordered protein re-

gions (IDPRs) are proteins or protein segments that do not maintain a stable,
rigid three-dimensional structure in physiological conditions. Rather, they are
found in a dynamic ensemble of structures that vary continuously over time
while inside the cell. Disordered regions are common in eukaryotic proteomes,
especially in regulatory proteins, and serve key roles when functional.
Roles in the Cell
1)IDPs play central roles in cellular signaling, the regulation of transcrip-
tion/translation, the control of the cell cycle, and the assembly of macro-
molecular complexes.
2)IDPs can undergo post-translational modifications and have alternative
splicing, which increases the regulatory complexity and specificity of actions
across tissues.
3)Disordered regions play a role as hubs for binding partners in protein-
protein interactions networks, acting in molecular recognition with short linear
motifs and/or fuzzy, dynamic ways.
4)IDPs also play a role in phase separation, forming membrane-less or-
ganelles, and thereby, compartmentalisation of cellular processes.

The two main approaches to evaluate the domains are experimental and com-
putational .
EXPERIMENTAL:Circular Dichroism (CD) spectroscopy,Nuclear Magnetic Reso-
nance (NMR),X-ray crystallography and COMPUTATIONAL:PONDR, IUPred,
DISOPRED, PrDOS, FoldIndex
2126(25)00316-8

This work presents high-resolution cryo-EM structures of human GAT3 in its

apo and inhibitor (SNAP-5114) bound states. Both structures showed an in-
ward-open conformation. This work highlights important substrate-binding
residues, the chloride binding site, and how SNAP-5114 binds to block trans-
port in the orthosteric pocket.

Major Results
-GAT3 adopts a classic NSS-family structure with conserved Na⁺/Cl⁻ binding
sites.
-SNAP-5114 occupies the substrate pocket, mimicking GABA, but forms addi-
tional hydrophobic interactions not observed in the GAT1 scaffolding.
-Mutagenesis confirms that residues E66, Y147, F308, and S309 are critical for
binding.
-The inhibitor is likely trapping GAT3 in a non-transporting conformation, pro-
viding additional evidence for a noncompetitive inhibition mechanism.
-Structural differences from GAT1 provide insight into subtype selectivity.
Critical Appraisal & Open Questions
While this study is an important step forward, there are several points to con-
template or ponder:
Strengths
Structural resolution (3.4-3.5 Å) is reasonable for modelling ligand/protein in-
teractions (especially in the transmembrane core).
The combination of both apo and inhibitor-bound states provides an opportu-
nity to compare and reasonably infer ligand-induced conformational changes
(or lack thereof).
The combination with mutagenesis/function (uptake) assays bolsters the as-
signment of interacting residues.
The presence of a truncated chloride ion density supports the correct ion-
binding assignments in the transporter core.
The additional perspective gained regarding the subtype selectivity is a valu-
able consideration for drug design (i.e. how GAT3 will differ from GAT1).
The finding that SNAP-5114 binds at the site of substrate, but inhibits non
competitively (i.e. "by stalling conformation"), is interesting from a conceptual
perspective and provides potential new paradigms for transporter inhibition.
Limitations
All the data is presented as inward-open states. Outward-open states are
missing
No clear image to observe Na⁺ density therefore not clear in terms of ion cou-
pling
1) Calculate the total volume of the nicotinic receptors and mus-
carinic receptors. Comment on the nature of the proteins.

I considered human α4β2 nicotinic acetylcholine receptor (PDB: 5KXI) AND

MUSCARIC RECEPTOR M2 Human Muscarinic Acetylcholine Receptor:
[Link] Protein Structure Obtained the PDB file of the
receptor ,Cleaned the PDB file by removing unwanted heteroatoms or wa-
ter molecules ,Saved the cleaned structure for further [Link] the
sphgen program within DISI to flood the protein surface with [Link]
generated .sph files that cover the protein’s surface and [Link]
sphere_selector tool to select sphere clusters representing the entire pro-
tein or specific binding [Link] the selected spheres for volume cal-
[Link] the volume_cal_sph.py Python script provided by DISI to
calculate the volume of the selected sphere [Link] output contained
volume details in cubic angstroms.
Human α4β2 Nicotinic Receptor-348,00 Cubic Angstroms
Human M2 Muscarinic Receptor (3UON)-86,000 Cubic angstroms
5) Two structurally related compounds have comparable receptor
affinity. Compound Xshows high plasma protein binding (98%),
whereas Compound Y has low protein binding(30%) but high hepato-
toxicity. Evaluate which compound is more suitable for further devel-
opment (defend your choice based on ADMET considerations).

Anti-cancer drug development often involves balancing efficacy and toxicity.

When evaluating two structurally related compounds for further development,
plasma protein binding and toxicity profiles are two important parameters to
consider in the context of ADMET (Absorption, Distribution, Metabolism, Excre-
tion, and Toxicity). In this example, Compound X has a high plasma protein
binding (~98%) which demonstrates that most, if not all, of the drug molecule
binds to plasma proteins (albumin). While the binding reduces the drug con-
centration of the free, pharmacologically active drug in circulation, binding can
serve as a reservoir for drug molecules that release the drug in a slower man-
ner which in turn can prolong the half life as well as maintain a more stable
plasma concentration over time. In other words, when a compound binds to
protein, it can reduce sudden free drug spikes in concentration and potential
toxicity and thereby improve safety. Protein binding also impacts the distribu-
tion of the drug throughout the body, with the binding limiting the volume of
distribution somewhat but preventing rapid clearance which can be beneficial
for sustaining plasma drug concentrations (and potentially allowing less fre-
quent dosing). However, considerations in dose optimisation should also be
taken into account with limited free drug [Link] comparison, Com-
pound Y has low plasma protein binding so that about 30% of the drug is avail-
able to bind, while a greater percentage of drug is unbound. Since more of the
drug is available right away to distribute to its intended targets, this is ex-
pected to produce greater efficacy at the receptor. However, the issue of this
compound to produce high levels of hepatotoxicity also exists. Hepatotoxicity
is a significant adverse effect and is notoriously challenging to deal with in an
ongoing clinical trial, often contributing to medication research being discon-
tinued or abandoned altogether. Hepatotoxicity is also a common reason for
liver injury. Hepatotoxicity is clinically relevant because it leads to a very nar-
row therapeutic window for the compound and impacts safe dosing. Although
low protein binding is beneficial to maintain free drug levels, the possibility of
liver injury is a serious safety issue that may occur at doses that would be con-
sidered safe for other drugs based solely on [Link] at AD-
MET, the safer toxicity profile of Compound X is a major reason to proceed.
High plasma protein binding will impose pharmacokinetic challenges that may
be mitigated through careful formulation and dose selection, whereas the high
hepatotoxicity represents a fundamental safety risk that could end develop-
ment altogether. Although the pharmacokinetic properties of Compound X sug-
gest a more straightforward clinical pharmacological profile, balancing efficacy
with sustained systemic exposure and decreased acute vision toxicity, Com-
pound Y raises deeply concerning issues regarding patient safety, regulatory
burdens, and development costs due to its hepatotoxicity.
In conclusion, taking into consideration the pharmacokinetic and toxicological
components, Compound X, despite high protein binding, has a better chance of
progressing into drug development compared with Compound Y, due to lower
6. Download [Link] from RCSB PDB, [Link] and build a homology
model in
SWISS-MODEL using 1HEL sequence as input. Compute quality metrics
for all three and present the output as a table. Evaluate Ramachan-
dran % allowed/disallowed, RMSD of Cα atoms (overlay in PyMOL/
Chimera), Average B-factors, Clashscore (MolProbity), Active site
pocket volume (CASTp or PyMOL plugin) and evaluate which structure
best represents the biologically relevant conformation. Discuss

Here is a evaluation of the three structures—1HEL (X-ray crystal structure), 7LYZ

(another related protein structure), and the homology model built on 1HEL se-
quence—in terms of the requested quality metrics and their biological relevance:
Ramachandran Plot (% Allowed/Disallowed):
X-ray Structures (1HEL, 7LYZ):
. Commonly exhibit a very high percentage of allowed residues (>90-95%)
and minimal disallowed regions, if relatively well-refined. This supports the pres-
ence of good backbone conformations that are commonly observed in experi-
mentally solved proteins.
• Homology Model: Often has a slightly lower percentage of allowed residues
(~85-95%) and will likely contain some disallowed conformations due to limita-
tions within the homology modeling process or inevitable differences between
homology model templates and targets.

RMSD of Cα Atoms (Structural Overlay):

• 1HEL vs. 7LYZ: RMSD values are typically low (<2 Å) for high-resolution
crystal structures from the same family of proteins, which indicates that their
backbone folds are quite similar to one another.
• Homology Model vs. 1HEL: RMSD values may be higher (~1.5–3 Å) due to
model uncertainties, especially in loop regions and placements of side chains,
compared to both high-resolution crystal structures and experimental data.

Average B-factors:
• 1HEL, 7LYZ: Typically vary between moderately low to moderate B-factors,
which reflect atomic thermal vibrations and/or thermal disorder in the crystal
packing; while also identifying flexible/disordered regions with higher B-factors
within the structure.
• Homology Model: Typically does not display B-factors because it is a theo-
retical, computational structure unless later added indirectly.

Clashscore (via MolProbity):

• X-ray Structures: Typically low (<10) if the structure was relatively well-re-
fined with a clashscore suggesting minimally impacted residues via steric
clashes during refinement.
• Homology Model: May have higher clashscores on average due to the less
optimized packing of side-chains and due to using a computational model that
contains multiple built-in inaccuracies as compared to a well-refined crystal
General Evaluation
• 1HEL is probably the best reflection of the biologically relevant
conformation, as it is an experimental structure with refined geometry, well-
placed side chains, and reliable pocket structure.
• 7LYZ is another reasonable structure, but small differences and
variability may still be present due to experimental conditions or crystal
packing, it can still be used to validate or compare conformation flexibility.
• A homology model is helpful if there is no experimental structure
to reference, or if you want to analyse sequence variants or use an experi-
mental (but not necessarily homologous) structure. However, homology mod-
els are considered less reliable for detailed atomic level conclusions, espe-
cially at a structural interpretation level, due to the propensity to produce
less reliable models in some areas.
The three structures - 1HEL (experimental X-ray), 7LYZ (another experimental
structure), and the homology model representing the 1HEL sequence - each
have unique strengths and weaknesses that factor into their biological rele-
vance.
The 1HEL structure, an experimentally determined X-ray crystallographic struc-
ture, has the key strength of being almost indisputably accurate with respect to
atomic positions and backbone geometry. It will routinely have well-defined Ra-
machandran statistics, low clashscores, B-factors that generally reflect atomic
flexibility, the active site pockets that are accurately defined based on real
data, and so on. This is typically used as the 'gold standard' for structural and
functional studies. Nonetheless, one must consider that crystal packing and ex-
perimental conditions may sometimes induce conformational artifacts, and
therefore represents one 'snapshot' of multiple biologically relevant states.
The 7LYZ structure, as another experimental structure for a family of the same
or similar protein, may be useful in performing comparative analysis, and eval-
uating conformational variability; its quality is likely similar to 1HEL in terms of
resolution and refinement. Similar to the other examples, the strengths of this
structure would provide an alternative conformation or ligand state, while limi-
tations could include that subtle changes may occur due to crystal packing or
4. Design a oligopeptide (more than 2 residues) based inhibitor
against CDK2. Elaborate on the steps used.

Designed Oligopeptide Inhibitor Sequence

Peptide: Arg-Gly-Ser-Pro (R-G-S-P)

The process of designing an oligopeptide inhibitor against CDK2 (Cyclin-De-

pendent Kinase 2) will be described as a process requiring multiple steps
combining structural biology, computational drug design, and biochemical ra-
tionale. The following workflow summarizes these processes:
Step 1: Understand the Structure and Function of CDK2
• Obtain a high-resolution crystal structure from the Protein Data
Bank of CDK2
• Examine the ATP-binding pocket and the substrate-binding pock-
ets, as competitive inhibitors generally bind to the ATP-binding cleft.
• Identify previously characterized peptide substrates or protein reg-
ulators that interact with CDK2.
Step 2: Identify Key Binding Sites and Hotspots
• Employ computational methodologies, for example, molecular
docking, molecular dynamics simulations, and hot spot mapping to identify
key amino acid residues necessary for ligand binding to the ATP-like site, or
for substrate binding.
• Examine key residues that facilitate hydrogen bonding, hydropho-
bic interactions and/or electrostatic complementarity.
• FTMap or LigPlot are computational tools to examine specific inter-
action hotspot identification on the CDK2 protein target.
Step 3: Choose Initial Peptide Motif
• Select or develop a small peptide sequence (3-10 residues) simu-
lating natural substrates or CDK2 inhibitors.
• For the peptide, rely on known cyclin or substrate motifs that inter-
act with the active site, or use peptide libraries that engage kinase domains
confirming binding.
• Choose peptide backbone and side chains capable of engaging key
interactions.
Step 4: Peptide Modification and Optimization
• Modify peptides to impact binding affinity:
• Add residues that provide better hydrogen bonding or hydrophobic
interactions.
• Add non-natural amino acid(s) or D-amino acids to promote stabil-
ity and resist proteolysis.
• Cyclize the peptide, if needed, to lock orientation and limit entropy
cost of binding.
Step 5: In Silico Docking and Scoring
• Use a molecular docking program (e.g., AutoDock, Glide, Rosetta
FlexPepDock) to dock the peptide inhibitor into the CDK2 binding pocket.
• Assess the binding poses, interaction profiles, and docking scores
in the process of selecting promising peptide sequences.
Design reasoning and procedures
1. Target selection: CDK2 is known to recognize substrate motifs that involve phospho-
rylation of serine or threonine residues followed by a proline (S/T-P motif). Therefore,
a peptide was designed with Ser-Pro at the C-terminus to effectively mimic this
recognition event.
2. Key residues: Arginine (Arg, R): This residue was chosen and placed on the peptide
backbone so that it could establish favorable electrostatic and hydrogen bonding in-
teractions with negatively charged residues or backbone atoms which are located
near the ATP-binding site of CDK2. Glycine (Gly, G):It was important to include this
residue to create spatial flexibility to accommodate binding within the cleft. Serine
(Ser, S): This was included in the sequence to serve as a phosphorylation site mimic
and can engage in hydrogen bonds with the kinase active site. Proline (Pro, P): CDK2
recognizes proline as the desired residue to follow the phosphorylation site, so this
was important to include in establishing occupancy of the substrate binding site.
3. Binding Interaction: The peptide insertion must bind within or near the ATP-binding
cleft of CDK2 to compete with the binding of the natural substrate, this is essential
for its function. Additional hydrogen bonds with the Ser residue possess a catalytic
residue and hydrogen bond or backbone contacts (so this phosphate mimetic residue
can make) the peptide more tightly bound to CDK2. In addition, the Arg residue im-